ASCO23: pembrolizumab plus chemotherapy improves overall survival for advanced cervical cancer patients

A study that will be presented at the 2023 ASCO Annual Meeting (2−6 June, IL, USA) has highlighted favorable survival results for advanced cervical cancer patients given Keytruda® (pembrolizumab) plus chemotherapy, with or without Avastin® (bevacizumab). The results support a possible new standard of care for the first-line treatment for this patient population. The KEYNOTE-826 study involved 617 patients with persistent, recurrent, or metastatic cervical cancer. The results obtained at a median follow up demonstrated an overall survival rate of 26.4 months in the pembrolizumab group vs 16.8 in the placebo group. Progression-free survival rate was 10.4 months in the...